In addition, SETD2 mutations have been linked to poor clinical prognosis in various tumors, such as in renal clear cell carcinoma and AML (Wang et al., 2019; González-Rodríguez et al., 2020). The gene discussed is SETD2; the disease is acute myeloid leukemia.